دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Image gallery: first take a good picture, then tell a good story
N. Rajan
doi : 10.1111/bjd.19534
Volume 184, Issue 1, January 2021, Pages: 1
The importance of provided information in contact allergy: key predictors on the road to success in the control of allergic contact dermatitis
P. Korkmaz, A. Boyvat
doi : 10.1111/bjd.19432
Volume 184, Issue 1, January 2021, Pages: 2
Complete skin clearance and beyond
M. Schmitt?Egenolf
doi : 10.1111/bjd.19544
Volume 184, Issue 1, January 2021, Pages: 3-4
Survival is excellent for most patients with thin melanoma, but patients may die from thin melanoma
L.M. Hollestein, T. Nijsten
doi : 10.1111/bjd.19208
Volume 184, Issue 1, January 2021, Pages: 4
The incidence of bullous pemphigoid continues to increase in England
C.E. Bax, V.P. Werth
doi : 10.1111/bjd.19207
Volume 184, Issue 1, January 2021, Pages: 5-6
Risk of infections in psoriasis. A lesson to learn during the SARS?CoV?2 pandemic
L. Naldi
doi : 10.1111/bjd.19190
Volume 184, Issue 1, January 2021, Pages: 6
In this issue of the BJD, Yiu et al. present risk estimates of severe infections in patients with psoriasis from the UK, based on record linkage analyses of administrative and clinical databases, during the period April 2003 to December 2016.1 People with psoriasis had a 36% increased risk of being hospitalized and a 33% increased risk of death due to infection compared with matched controls. While the risk of infection increased with active psoriasis, no further increase in risk was documented for severe psoriasis, identified by the prescription of systemic therapies. Notably, risk estimates were adjusted for important confounding factors and comorbid conditions, supporting the notion that psoriasis per se may be linked with the increased risk.
Reliable assessment of atopic dermatitis severity: do we need more tools?
A. Reich
doi : 10.1111/bjd.19392
Volume 184, Issue 1, January 2021, Pages: 6-7
Caffeine relaxes hair follicles in androgenetic alopecia
M. Ohyama
doi : 10.1111/bjd.19388
Volume 184, Issue 1, January 2021, Pages: 7-8
Ubiquitin, a novel therapeutic target in psoriasis?
R.F.L. O’Shaughnessy
doi : 10.1111/bjd.19332
Volume 184, Issue 1, January 2021, Pages: 8-9
The modulating effect of dermal–epidermal crosstalk on the repair efficiency of cyclobutane pyrimidine dimers in keratinocytes
J. Cadet
doi : 10.1111/bjd.19334
Volume 184, Issue 1, January 2021, Pages: 9-10
First real?world data provide evidence for a ‘window of opportunity’ in treatment of hidradenitis suppurativa/acne inversa
C.C. Zouboulis
doi : 10.1111/bjd.19165
Volume 184, Issue 1, January 2021, Pages: 10-11
Drug registrations require a standardized sequence of randomized controlled trials (RCTs). In an effort to reduce certain sources of bias when testing the effectiveness of new treatments, RCTs may, to some extent, exclude patients who could jeopardize the efficacy and safety results.
Impaired type I interferon response in SARS?CoV?2 infection: looking through the cutaneous window
D. Bessis
doi : 10.1111/bjd.19596
Volume 184, Issue 1, January 2021, Pages: 11-12
Since the beginning of the coronavirus disease 2019 (COVID?19) pandemic, strong evidence has accumulated for the key role of an inappropriate, insufficient, overactive and/or delayed type I (mainly alpha and beta) interferon response during SARS?CoV?2 infection. Most studies have concerned critically ill patients with COVID?19 and the results have been discrepant and even contradictory. This likely reflects differences in the criteria of the studies, such as timing of sampling, nature of the affected organs, severity of the disease and presence of comorbidities.
What should be in the facial patch testing series for 2020?
W. Boonchai
doi : 10.1111/bjd.19245
Volume 184, Issue 1, January 2021, Pages: 13
Role of regulatory T cells in psoriasis pathogenesis and treatment
L. Nussbaum, Y.L. Chen, G.S. Ogg
doi : 10.1111/bjd.19380
Volume 184, Issue 1, January 2021, Pages: 14-24
Psoriasis is a chronic inflammatory disease with a strong genetic component that can be triggered by environmental factors. Disease pathogenesis is mainly driven by type 1 and type 17 cytokine?producing cells which, in healthy individuals, are modulated by regulatory T cells (Tregs). Tregs play a fundamental role in immune homeostasis and contribute to the prevention of autoimmune disease by suppressing immune responses. In psoriasis, Tregs are impaired in their suppressive function leading to an altered T?helper 17/Treg balance.
Therapeutic options for erosive pustular dermatosis of the scalp: a systematic review
M.H. Junejo J. Kentley M. Rajpopat X.L. Tan M. Firouz Mohd Mustapa C.A. Harwood
doi : 10.1111/bjd.19026
Volume 184, Issue 1, January 2021, Pages: 25-33
Erosive pustular dermatosis of the scalp (EPDS) is a chronic condition characterized by erosive plaques and subsequent scarring alopecia as a result of local trauma or inflammation. A number of therapeutic approaches have been described in the literature but there is no consensus of opinion on optimal treatment of the disease.
Is psoriasis associated with dementia or cognitive impairment? A Critically Appraised Topic
H. Yen H. Yen C.?C. Chi
doi : 10.1111/bjd.19025
Volume 184, Issue 1, January 2021, Pages: 34-42
Psoriasis is a multisystemic inflammatory disorder that has an unclear association with cognitive dysfunction.
Intervention study to evaluate the importance of information given to patients with contact allergy: a randomized, investigator?blinded clinical trial
A. Dizdarevic W. Troensegaard A. Uldahl O. Bergendorff I. Siemund ?. Svensson A. Sonesson
doi : 10.1111/bjd.19119
Volume 184, Issue 1, January 2021, Pages: 43-49
In contact dermatitis, it is crucial to understand and remember the outcome of patch testing. Unfortunately, many patients do not remember the results of their patch tests.
Efficacy and safety of risankizumab vs. secukinumab in patients with moderate?to?severe plaque psoriasis (IMMerge): results from a phase III, randomized, open?label, efficacy–assessor?blinded clinical trial
R.B. Warren A. Blauvelt Y. Poulin S. Beeck M. Kelly T. Wu Z. Geng C. Paul
doi : 10.1111/bjd.19341
Volume 184, Issue 1, January 2021, Pages: 50-59
Patients with plaque psoriasis treated with biologic therapies need more efficacious, safe and convenient treatments to improve quality of life. Risankizumab and secukinumab inhibit interleukin?23 and interleukin?17A, respectively, and are effective in adult patients with moderate?to?severe plaque psoriasis but have different dosing regimens.
Survival in 31 670 patients with thin melanomas: a Swedish population?based study
K. Isaksson R. Mikiver H. Eriksson J. Lapins K. Nielsen C. Ingvar J. Lyth
doi : 10.1111/bjd.19015
Volume 184, Issue 1, January 2021, Pages: 60-67
The incidence of cutaneous malignant melanoma (CMM) continues to increase in most countries worldwide and the majority are diagnosed with thin tumours (? 1 mm).
Incidence, prevalence and mortality of bullous pemphigoid in England 1998–2017: a population?based cohort study
M.S.M. Persson K.E. Harman Y. Vinogradova S.M. Langan J. Hippisley?Cox K.S. Thomas S. Gran
doi : 10.1111/bjd.19022
Volume 184, Issue 1, January 2021, Pages: 68-77
A rising incidence and high mortality were found for bullous pemphigoid (BP) over a decade ago in the UK. Updated estimates of its epidemiology are required to understand the healthcare needs of an ageing population.
Risk of hospitalization and death due to infection in people with psoriasis: a population?based cohort study using the Clinical Practice Research Datalink
Z.Z.N. Yiu R. Parisi M. Lunt R.B. Warren C.E.M. Griffiths S.M. Langan D.M. Ashcroft
doi : 10.1111/bjd.19052
Volume 184, Issue 1, January 2021, Pages: 78-86
Psoriasis is associated with risk factors for serious infections, but the independent relationship between psoriasis and serious infection is as yet unclear.
Measurement properties of the Rajka–Langeland severity score in children and adults with atopic dermatitis
J.I. Silverberg D. Lei M. Yousaf S.R. Janmohamed P.P. Vakharia R. Chopra R. Chavda S. Gabriel K.R. Patel V. Singam R. Kantor Derek Y. Hsu
doi : 10.1111/bjd.19159
Volume 184, Issue 1, January 2021, Pages: 87-95
Multiple atopic dermatitis (AD) severity scales exist, with no gold standard for use in clinical practice.
New effects of caffeine on corticotropin?releasing hormone (CRH)?induced stress along the intrafollicular classical hypothalamic–pituitary–adrenal (HPA) axis (CRH?R1/2, IP3?R, ACTH, MC?R2) and the neurogenic non?HPA axis (substance P, p75NTR and TrkA) in ex vivo human male androgenetic scalp hair follicles
T.W. Fischer A. Bergmann N. Kruse K. Kleszczynski C. Skobowiat A.T. Slominski R. Paus
doi : 10.1111/bjd.19115
Volume 184, Issue 1, January 2021, Pages: 96-110
Human hair is highly responsive to stress, and human scalp hair follicles (HFs) contain a peripheral neuroendocrine equivalent of the systemic hypothalamic–pituitary–adrenal (HPA) stress axis. Androgenetic alopecia (AGA) is supposed to be aggravated by stress. We used corticotropin?releasing hormone (CRH), which triggers the HPA axis, to induce a stress response in human ex vivo male AGA HFs. Caffeine is known to reverse testosterone?mediated hair growth inhibition in the same hair organ culture model.
Upregulated E3 ligase tripartite motif?containing protein 21 in psoriatic epidermis ubiquitylates nuclear factor??B p65 subunit and promotes inflammation in keratinocytes
L. Yang T. Zhang C. Zhang C. Xiao X. Bai G. Wang
doi : 10.1111/bjd.19057
Volume 184, Issue 1, January 2021, Pages: 111-122
Tripartite motif?containing protein 21 (Trim21) is an E3 ubiquitin?protein ligase that plays pivotal roles in various diseases. However, its role in mediating keratinocyte inflammation, which is a hallmark of psoriasis, has not been thoroughly elucidated.
The use of tissue?engineered skin to demonstrate the negative effect of CXCL5 on epidermal ultraviolet radiation?induced cyclobutane pyrimidine dimer repair efficiency
M.M. Dorr R. Guignard F.A. Auger P.J. Rochette
doi : 10.1111/bjd.19117
Volume 184, Issue 1, January 2021, Pages: 123-132
Ultraviolet radiation (UVR) is responsible for keratinocyte cancers through the induction of mutagenic cyclobutane pyrimidine dimers (CPDs). Many factors influence CPD repair in epidermal keratinocytes, and a better understanding of those factors might lead to prevention strategies against skin cancer.
Evidence for a ‘window of opportunity’ in hidradenitis suppurativa treated with adalimumab: a retrospective, real?life multicentre cohort study
A.V. Marzano G. Genovese G. Casazza C. Moltrasio P. Dapavo G. Micali R. Sirna P. Gisondi A. Patrizi V. Dini D. Bianchini L. Bianchi L. Fania F. Prignano A. Offidani L. Atzori V. Bettoli S.P. Cannav? M. Venturini M. R. Bongiorno A. Costanzo G. Fabbrocini K. Peris
doi : 10.1111/bjd.18983
Volume 184, Issue 1, January 2021, Pages: 133-140
The anti?tumour necrosis factor (TNF)?? adalimumab is the only licenced biologic for moderate?to?severe hidradenitis suppurativa (HS). No predictors of response have been identified so far.
The differing pathophysiologies that underlie COVID?19?associated perniosis and thrombotic retiform purpura: a case series
C.M. Magro J.J. Mulvey J. Laurence S. Sanders A.N. Crowson M. Grossman J. Harp G. Nuovo
doi : 10.1111/bjd.19415
Volume 184, Issue 1, January 2021, Pages: 141-150
There are two distinctive acral manifestations of COVID?19 embodying disparate clinical phenotypes. One is perniosis occurring in mildly symptomatic patients, typically children and young adults; the second is the thrombotic retiform purpura of critically ill adults with COVID?19.
What is in? What is out? Updating the British Society for Cutaneous Allergy facial series
S. Rolls E. Owen C.G. Bertram J.F. Bourke D.A. Buckley M.M.U. Chowdhury S.M. Cooper S.A. Ghaffar C.M. Green T.M. Hughes G.A. Johnston C.M. Reckling D.A. Thompson S.H. Wakelin M. Wilkinson N.M. Stone
doi : 10.1111/bjd.19127
Volume 184, Issue 1, January 2021, Pages: 151-155
Allergic contact dermatitis (ACD) to cosmetics is widely reported. To ensure we are accurately diagnosing ACD, patch test series should be continually reviewed to identify relevant and emerging allergens and highlight those that are outdated. The current British Society for Cutaneous Allergy (BSCA) facial series recommends 26 allergens and was last modified in 2012.
Villainous hair: ba(l)d to the bone – would they be so evil if they had hair?
G. Kyriakou V. Drivelou A. Glentis
doi : 10.1111/bjd.19508
Volume 184, Issue 1, January 2021, Pages: 156-157
Racial and ethnic differences in the clinical presentation and outcomes of acral lentiginous melanoma
S. Behbahani S. Malerba F.H. Samie
doi : 10.1111/bjd.19406
Volume 184, Issue 1, January 2021, Pages: 158-160
Characterizing physical symptoms of flare in hidradenitis suppurativa: a patient survey
J.M. Fernandez A.M. Thompson J.S. Kirby J.L. Hsiao V.Y. Shi
doi : 10.1111/bjd.19412
Volume 184, Issue 1, January 2021, Pages: 160-162
A relapsing localized variant of neutrophilic dermatosis triggered by tissue injury
A.D. Gloor L. Feldmeyer A. Rammlmair C. Schlapbach D. Wallach L. Borradori
doi : 10.1111/bjd.19418
Volume 184, Issue 1, January 2021, Pages: 162-164
Treatment?resistant tinea corporis, a potential public health issue
E. Chen M. Ghannoum B.E. Elewski
doi : 10.1111/bjd.19420
Volume 184, Issue 1, January 2021, Pages: 164-165
What is successful repigmentation in vitiligo from the point of view of patients?
V.S. Narayan S.E. Uitentuis M.W. Bekkenk A. Wolkerstorfer
doi : 10.1111/bjd.19422
Volume 184, Issue 1, January 2021, Pages: 165-166
Omalizumab for the treatment of chronic inducible urticaria in 80 patients
V. Exposito?Serrano L. Curto?Barredo P. Aguilera Peiro S. G?mez Armayones E. Serra?Baldrich J. Spertino M. Bonfill Ort? I. Figueras Nart G. Melé?Ninot C. Baliu?Piqué A. Sala Cunill M. Labrador?Horrillo A. Guilabert Vidal N. Fern?ndez Chico A.M. Giménez?Arnau
doi : 10.1111/bjd.19425
Volume 184, Issue 1, January 2021, Pages: 167-168
Evaluation of ‘not relevant’ responses on the Dermatology Life Quality Index (DLQI) and the DLQI?R scoring modification among Indian patients with vitiligo
V. Gupta N. Taneja H.C. Sati V. Sreenivas M. Ramam
doi : 10.1111/bjd.19424
Volume 184, Issue 1, January 2021, Pages: 168-169
Disparities in outcomes of CD8+ cutaneous T?cell lymphoma by race and presenting lesion location
F. N. Mirza S. Yumeen M. Girardi
doi : 10.1111/bjd.19426
Volume 184, Issue 1, January 2021, Pages: 170-171
The reliability of the Self?Assessment Cutaneous Inflammatory Disease Extent Score (SA?CIDES) and the rule of hands to assess the involved body surface area in psoriasis and eczema
R. Speeckaert J. Lambert L. Delbaere T. Lesseliers N. van Geel
doi : 10.1111/bjd.19430
Volume 184, Issue 1, January 2021, Pages: 171-173
Intralesional cryosurgery of keloids: required treatment hold time
C. C. Zouboulis T. Wild V. A. Zouboulis Y. Har?Shai
doi : 10.1111/bjd.19427
Volume 184, Issue 1, January 2021, Pages: 173-175
Drug survival of systemic and biological treatments for moderate?to?severe atopic dermatitis in adults: a multicentre retrospective observational study
J.J. Pereyra?Rodriguez J. Dom?nguez?Cruz R. Ruiz?Villaverde J.F. Silvestre M. Gal?n L. Curto I. Figueras E. Serra?Baldrich J.C. Armario?Hita
doi : 10.1111/bjd.19428
Volume 184, Issue 1, January 2021, Pages: 175-176
Diagnosis of mycoplasma aetiology in Stevens–Johnson syndrome/toxic epidermal necrolysis
E. Russell S. Walker T. McPherson
doi : 10.1111/bjd.19458
Volume 184, Issue 1, January 2021, Pages: 176-178
Nailfold capillary abnormalities: a possible cause for nail psoriasis?
F. Long F. He J. Wang L. Wang J. Tu Z. Zhang J. Xia Z. Yin Y. Lu
doi : 10.1111/bjd.19466
Volume 184, Issue 1, January 2021, Pages: 178-180
Occupational dermatology in the time of the COVID?19 pandemic: a report of experience from London and Manchester, UK
F.J. Ferguson G. Street L. Cunningham I.R. White J.P. McFadden J. Williams
doi : 10.1111/bjd.19482
Volume 184, Issue 1, January 2021, Pages: 180-182
COVID?19 in patients with hidradenitis suppurativa
X.T. Lima M.A. Cueva M.B. Alora
doi : 10.1111/bjd.19492
Volume 184, Issue 1, January 2021, Pages: 182-184
Prevalence of mucocutaneous manifestations in 666 patients with COVID?19 in a field hospital in Spain: oral and palmoplantar findings
A. Nuno?Gonzalez P. Martin?Carrillo K. Magaletsky M.D. Martin Rios C. Herranz Ma?as J. Artigas Almazan G. Garc?a Casasola E. Perez Castro A. Gallego Arenas A. Mayor Ibarguren M. Feito Rodr?guez B. Lozano Masdemont M. Beato E. Ruiz Bravo P. Oliver M.D. Montero Vega P. Herranz Pinto
doi : 10.1111/bjd.19564
Volume 184, Issue 1, January 2021, Pages: 184-185
SARS?CoV?2 has not been detected directly by electron microscopy in the endothelium of chilblain lesions
J.K. Brealey S.E. Miller
doi : 10.1111/bjd.19572
Volume 184, Issue 1, January 2021, Pages: 186
SARS?CoV?2 has not been detected directly by electron microscopy in the endothelium of chilblain lesions: reply from the authors
I. Colmenero C. Santonja M. Alonso?Ria?o D. Andina J.L. Rodr?guez Peralto L. Requena A. Torrelo
doi : 10.1111/bjd.19595
Volume 184, Issue 1, January 2021, Pages: 186-187
The pharmacology of itch
J.R. Ingram A. Ahluwalia
doi : 10.1111/bjd.18525
Volume 184, Issue 1, January 2021, Pages: e1-e2
Noninvasive real?time imaging of mite skin infestations with line?field confocal optical coherence tomography
C. Ruini S. Schuh D. Hartmann L. French J. Welzel E. Sattler
doi : 10.1111/bjd.19318
Volume 184, Issue 1, January 2021, Pages: e3
Treatment of multiple facial basal cell carcinomas in a child with xeroderma pigmentosum complementation group C with Mohs micrographic surgery
A. Greig K. Aloni G. Orchard M. Shams E. Craythorne H. Fassihi
doi : 10.1111/bjd.19323
Volume 184, Issue 1, January 2021, Pages: e4
Prurigo pigmentosa and new?onset type 1 diabetes in a black female patient testing positive for SARS?CoV?2 IgG
K.M. Derrick D.R. Mazori E.R. Heilman S.A. Glick
doi : 10.1111/bjd.19568
Volume 184, Issue 1, January 2021, Pages: e5
Oral vesiculobullous lesions as an early sign of COVID?19: immunohistochemical detection of SARS?CoV?2 spike protein
C.D. Soares A. Mosqueda?Taylor M.G.F. de Carvalho O.P. de Almeida
doi : 10.1111/bjd.19569
Volume 184, Issue 1, January 2021, Pages: e6
Trim21 promotes inflammation in keratinocytes of psoriatic patients
doi : 10.1111/bjd.19634
Volume 184, Issue 1, January 2021, Pages: e7
Psoriasis is a skin disease that manifests as itchy, scaly plaques (patches) on the skin. It is associated with both a physical and psychological burden, and affects 0.5?1% of children and 2?3% of the population worldwide.
A study of additional information given to patients with contact allergies
doi : 10.1111/bjd.19635
Volume 184, Issue 1, January 2021, Pages: e8
Contact dermatitis is a type of eczema caused by contact of the skin with a particular substance in the environment. This can cause a chronic skin disease such as hand eczema and it is crucial to identify the allergy and to obtain information on where the allergen can be found. Otherwise, the eczema becomes difficult to treat and may affect a patient’s daily life and work ability. More than a quarter of the European population has been shown to have some kind of contact allergy.
How well do treatments for erosive pustular dermatosis of the scalp work?
doi : 10.1111/bjd.19636
Volume 184, Issue 1, January 2021, Pages: e9
Erosive pustular dermatosis of the scalp (EPDS) is a skin disease that causes non?healing wounds on the scalp. It may be more common than previously thought, as it can be misdiagnosed. EPDS usually affects older patients with lots of sun damage, and it may also be caused by injury, surgery, or certain treatments used by dermatologists, such as 5?fluorouracil cream, which is used to treat pre?cancerous lesions.
Predicting the success of treating hidradenitis suppurativa with adalimumab
doi : 10.1111/bjd.19637
Volume 184, Issue 1, January 2021, Pages: e10
Hidradenitis suppurativa (HS) is a chronic skin disease affecting around 1% of the population and characterized by painful boil?like lumps, cysts and scarring on skin folds.
How does a diagnosis of thin cutaneous malignant melanoma affect survival rates?
doi : 10.1111/bjd.19638
Volume 184, Issue 1, January 2021, Pages: e11
Cutaneous malignant melanoma is a type of skin cancer that you can die from. The number of patients being diagnosed with malignant melanoma of the skin is rising in most countries. About 4000 patients were diagnosed in Sweden in 2018. The risk of dying from cutaneous melanoma is very much dependent on the thickness of melanoma, a measure given by the pathologist after removing the melanoma.
How many people have bullous pemphigoid in England?
doi : 10.1111/bjd.19639
Volume 184, Issue 1, January 2021, Pages: e12
Bullous pemphigoid is a distressing disease that causes blisters and itching of the skin. Our study, from England, aimed to find out how many people get bullous pemphigoid for the first time each year (incidence), how many people are living with bullous pemphigoid at any given point (prevalence), and whether people with bullous pemphigoid are more likely to die than similar people without the disease (mortality).
Do people with psoriasis have an increased risk of serious infection?
doi : 10.1111/bjd.19640
Volume 184, Issue 1, January 2021, Pages: e13
Psoriasis is a chronic inflammatory skin condition that is associated with (linked to) additional conditions such as diabetes and obesity (called comorbidities), which in turn are associated with an increased risk of infection. One concern people with psoriasis have is whether the psoriasis itself, rather than the comorbidities, is associated with an increased risk of getting a serious infection, which is defined as having any infection serious enough to lead to hospital admission.
Updating the British Society for Cutaneous Allergy Facial Series to ensure accurate diagnosis of allergic contact dermatitis
doi : 10.1111/bjd.19641
Volume 184, Issue 1, January 2021, Pages: e14
Allergic contact dermatitis (ACD) is a localised form of dermatitis or eczema which occurs 48?72 hours after a substance which causes allergy (an allergen) has been in contact with the skin. It affects 20% of people. ACD to cosmetics is widely reported, with facial eczema being the main presenting complaint.
Is risankizumab better than secukinumab in the treatment of plaque psoriasis?
doi : 10.1111/bjd.19642
Volume 184, Issue 1, January 2021, Pages: e15
Plaque psoriasis is a common inflammatory disease that causes raised, flaky plaques or patches on the skin. An abnormal immune system can be an important cause of psoriasis. Risankizumab and secukinumab are biologic drugs that are injected under a patient’s skin to treat different parts of the immune system. Both drugs are approved in the U. S. and E. U. to treat moderate?to?severe plaque psoriasis.
Is there a link between psoriasis and dementia?
doi : 10.1111/bjd.19643
Volume 184, Issue 1, January 2021, Pages: e16
Psoriasis and dementia are both common conditions. Because of how both diseases develop within the body, they might have certain shared traits, and it has been suggested that patients with psoriasis may be at greater risk of developing impaired mental function and/or dementia. This study from Taiwan examines the published research to see whether there may be evidence of such a link.
How good is the Rajka and Langeland score for assessing eczema?
doi : 10.1111/bjd.19646
Volume 184, Issue 1, January 2021, Pages: e17
Atopic dermatitis (AD) is a common type of eczema seen in people of all ages, particularly children. It makes the skin inflamed, itchy and sore and affects many aspects of everyday life. There is a lot of research into different treatments, but it is hard to compare them because researchers use different ways to measure how severe the eczema is.
Trim21 ?????????????????
doi : 10.1111/bjd.19647
Volume 184, Issue 1, January 2021, Pages: e18
??????????, ????????????? (????) ????????????, ??? 0.5?1% ???? 2?3% ????????
????????????????????
doi : 10.1111/bjd.19648
Volume 184, Issue 1, January 2021, Pages: e19
????????????????????????????????????????????, ????????????????????????????, ?????????, ??????????????????????????????????????????
??????????????????
doi : 10.1111/bjd.19649
Volume 184, Issue 1, January 2021, Pages: e20
????????? (EPDS) ??????, ????????????????????????????, ?????????EPDS ?????????????????, ???????????????????????? (??????????? 5??????) ???
??????????????????
doi : 10.1111/bjd.19650
Volume 184, Issue 1, January 2021, Pages: e21
?????? (HS) ????????, ?? 1% ???????, ??????????????????????
?????????????????????
doi : 10.1111/bjd.19651
Volume 184, Issue 1, January 2021, Pages: e22
????????????????????????/????????????????????????2018 ?, ???? 4000 ???????????????????????????????????????, ?????????????????????????????????????????????????????????, ???? 1 ??????
????????????????
doi : 10.1111/bjd.19652
Volume 184, Issue 1, January 2021, Pages: e23
?????????????????, ?????????????????????????????????????????? (???) ???????????????????? (???) ?????????????????????? (???) ?
?????????????????
doi : 10.1111/bjd.19653
Volume 184, Issue 1, January 2021, Pages: e24
???????????????, ????????? (?????) ??????? (??) , ?????????????????????????????, ????? (??????) ????????????????????????????????????
??????????????, ???????????????
doi : 10.1111/bjd.19654
Volume 184, Issue 1, January 2021, Pages: e25
???????? (ACD) ???????????, ???????? (???) ?????? 48?72 ??????? 20% ????????????? ACD ?????, ??????????
Risankizumab ???????????????????
doi : 10.1111/bjd.19655
Volume 184, Issue 1, January 2021, Pages: e26
?????????????????, ??????????????? (??) ?????????????????????Risankizumab ???????????????????????????????????????????????, ????????????????
??????????????
doi : 10.1111/bjd.19656
Volume 184, Issue 1, January 2021, Pages: e27
??????????????????????????????, ?????????????, ???????, ???????????????????/?????????????????????????????????????????
????? Rajka ? Langeland ??????
doi : 10.1111/bjd.19657
Volume 184, Issue 1, January 2021, Pages: e28
????? (AD) ??????? (?????) ??????????????????????????, ??????????????????????????, ?????????, ????????????????????????
